- Record: found
- Abstract: found
- Article: found
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts
Thomas K Karikari ,
Tharick A Pascoal ,
Nicholas J Ashton ,
Shorena Janelidze ,
Andréa Lessa Benedet ,
Juan Lantero Rodriguez ,
Mira Chamoun ,
Melissa Savard ,
Min Su Kang ,
Joseph Therriault ,
Michael Schöll ,
Gassan Massarweh ,
Jean-Paul Soucy ,
Kina Höglund ,
Gunnar Brinkmalm ,
Niklas Mattsson ,
Sebastian Palmqvist ,
Serge Gauthier ,
Erik Stomrud ,
Henrik Zetterberg ,
Oskar Hansson ,
Pedro Rosa-Neto ,
Kaj Blennow
May 2020
May 2020
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
CSF and PET biomarkers of amyloid β and tau accurately detect Alzheimer's disease
pathology, but the invasiveness, high cost, and poor availability of these detection
methods restrict their widespread use as clinical diagnostic tools. CSF tau phosphorylated
at threonine 181 (p-tau181) is a highly specific biomarker for Alzheimer's disease
pathology. We aimed to assess whether blood p-tau181 could be used as a biomarker
for Alzheimer's disease and for prediction of cognitive decline and hippocampal atrophy.